SCHEDULE 13D: Quanterix Corporation to Acquire Akoya Biosciences in Strategic Merger, Reshaping Single-Cell Imaging Landscape

Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences, Inc. through a merger, with Akoya becoming a wholly-owned subsidiary of Quanterix, significantly altering the combined entity's ownership structure and board composition.

Summary

• Quanterix Corporation (Issuer) and Akoya Biosciences, Inc. (Akoya) have entered into an Agreement and Plan of Merger dated January 9, 2025.
• Under the agreement, Akoya will merge with and into Wellfleet Merger Sub, Inc., a wholly-owned subsidiary of Quanterix, with Akoya continuing as the surviving entity and a wholly-owned subsidiary of Quanterix.
• Each outstanding share of Akoya common stock will be converted into the right to receive 0.318 shares of Quanterix Common Stock.
• Existing Akoya restricted stock units and stock options will be automatically converted into equivalent awards with respect to Quanterix Common Stock, maintaining their original vesting schedules and terms, with some equity awards potentially accelerating vesting.
• Upon completion of the merger, current Quanterix stockholders are expected to own approximately 70%, and Akoya stockholders approximately 30%, of the combined company on a fully diluted basis.
• Akoya Biosciences, Inc. currently beneficially owns 2,955,532 shares of Quanterix Common Stock, representing 6.2% of the outstanding shares, primarily due to a Voting Agreement.

Sentiment

Score: 7

Explanation: The document reports a strategic merger, which is generally viewed as a positive step for growth and market consolidation. While it's a factual regulatory filing, the underlying event (a merger) typically carries positive strategic implications for the involved companies, assuming successful integration and synergies.

Positives

• The merger is expected to create a combined entity with a broader market presence in single-cell imaging solutions.
• The transaction is structured to integrate Akoya as a wholly-owned subsidiary, potentially streamlining operations and strategic alignment.
• The inclusion of two Akoya nominees on the post-merger Quanterix Board of Directors suggests a collaborative integration approach.

Risks

• The consummation of the merger is subject to various conditions set forth in the Merger Agreement.
• The transaction requires the filing of a registration statement on Form S-4 with the SEC, which will contain a joint proxy statement/prospectus, indicating regulatory review and shareholder approvals are necessary.
• There is an inherent risk that the merger may not be completed if conditions are not met or if regulatory approvals are not obtained.

Future Outlook

The document outlines the definitive agreement for Akoya Biosciences to merge into a wholly-owned subsidiary of Quanterix Corporation. The completion of the merger is contingent upon the satisfaction of conditions outlined in the Merger Agreement and regulatory filings, including a Form S-4 registration statement and joint proxy statement/prospectus, which will be filed with the SEC.

Management Comments

• Akoya Biosciences, Inc. has not, and to the best of Akoya's knowledge, none of the persons listed on Schedule A attached hereto has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• Akoya Biosciences, Inc. has not, and to the best of Akoya's knowledge, none of the persons listed on Schedule A attached hereto has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Industry Context

This merger signifies a consolidation within the biotechnology sector, specifically in the single-cell imaging solutions market. Akoya Biosciences specializes in comprehensive single-cell imaging, allowing researchers to phenotype cells with spatial context, which is crucial for understanding disease progression and therapy response. Quanterix Corporation, also in the life sciences tools space, is expanding its capabilities and market share through this acquisition, potentially creating a more comprehensive offering in the precision health and diagnostics market.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the merger terms against industry standards. It focuses solely on the details of the specific transaction between Quanterix and Akoya.

Management Changes

Corporate Governance

Legal Proceedings

• Akoya Biosciences, Inc. has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• Akoya Biosciences, Inc. has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Stakeholder Impact

• Shareholders (Quanterix): Will own approximately 70% of the combined entity, potentially benefiting from expanded market reach and capabilities.
• Shareholders (Akoya): Will receive Quanterix common stock at an exchange ratio of 0.318 shares per Akoya share, owning approximately 30% of the combined entity. Their equity awards will convert to Quanterix awards.
• Employees (Akoya): Akoya will become a wholly-owned subsidiary of Quanterix, implying integration of operations and potential changes to employment structures, though not explicitly detailed.
• Management (Akoya): Two individuals nominated by Akoya will join the Quanterix Board, ensuring some continuity and representation at the governance level.

Next Steps

• Quanterix will file a registration statement on Form S-4 with the SEC, which will include a joint proxy statement/prospectus.
• Investors and security holders are urged to read the registration statement and joint proxy statement/prospectus carefully when they become available.
• A definitive copy of the joint proxy statement/prospectus will be mailed to Quanterix and Akoya stockholders when final.
• The merger is subject to the terms and conditions set forth in the Merger Agreement.

Key Dates

Keywords

Quanterix Corporation, Akoya Biosciences, Merger Agreement, SEC Filing, Schedule 13D, Biotechnology, Single-cell Imaging, Corporate Acquisition, Stock Exchange Ratio, Voting Agreement, Common Stock, SEC Form S-4